drugset
drugset / Trial / NCT05523687

AME Study of [14C]-PC14586 in Healthy Male Participants

NCT05523687 ↗

Phase 1 Completed 8 enrolled PMV Pharmaceuticals, Inc
NaSingle-groupOpen-labelOther

Summary

This study will assess the PK and rates of elimination and mass balance of total radioactivity from \[14C\]-PC14586

Timeline

Start
2022-09-06
Primary completion
2022-11-30
Completion
2022-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject rezatapopt Small molecule — Oral

Indications

No indication recorded.